Drug Trial Radar · NCT02196077
Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Jun 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Aug 1, 2014
Primary completion
Mar 1, 2015
Study completion Mar 1, 2015
Sponsor
- Lead sponsor
- Pearl Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIb, randomized, double blind, chronic dosing (28 days), four period, five treatment, incomplete block, crossover design in subjects with moderate to severe COPD. The overall objective is to demonstrate that the combination of budesonide (BD; PT008) and formoterol fumarate (FF; PT005) in a metered-dose inhaler (MDI); (BFF MDI; PT009) provides benefit on lung function compared with BD MDI in subjects with moderate to severe COPD.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
BFF MDI 320/9.6 μgDrug
Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
BFF MDI 160/9.6 μgDrug
Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
BFF MDI 80/9.6 μgDrug
Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
BD MDI 320 μgDrug
Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
FF MDI 9.6 μgDrug
Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
Primary outcomes
What the sponsor says the trial is designed to measure.
- FEV1 AUC0-12 on Day 29Time frame: Day 29
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Pearl Investigative Site
Rolling Hills Estates, California
Pearl Investigative Site
Clearwater, Florida
Pearl Investigative Site
Panama City, Florida
Pearl Investigative Site
Tampa, Florida
Pearl Investigative Site
Winter Park, Florida
Pearl Investigative Site
Edina, Minnesota
Pearl Investigative Site
Minneapolis, Minnesota
Pearl Investigative Site
Woodbury, Minnesota
Pearl Investigative Site
Saint Charles, Missouri
Pearl Investigative Site
Charlotte, North Carolina
Pearl Investigative Site
Cincinnati, Ohio
Pearl Investigative Site
Columbus, Ohio
Pearl Investigative Site
Dublin, Ohio
Pearl Investigative Site
Medford, Oregon
Pearl Investigative Site
Easley, South Carolina
Pearl Investigative Site
Greenville, South Carolina
Pearl Investigative Site
Spartanburg, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.